New treatments for tuberculosis that target bacteria inside human cells
Official title: New anti-tubercular agents targeting intracellular bacteria
Funded at Seattle Children's Hospital · NIH-11123212 · Data updated 2026-11-12
This study is looking for new medicines that can better fight the tuberculosis bacteria hiding inside our cells, with the hope of making treatment faster and more effective for people with TB.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | June 21, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $931,143 |
| NIH project number | 5R01AI173110-02 |
| Project ID | NIH-11123212 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those with drug-resistant strains or complications related to intracellular bacterial infections.
✕Less likely to help
Patients with non-tuberculosis bacterial infections or those who do not have active tuberculosis may not benefit from this research.
What this research studies
This research focuses on developing new anti-tubercular agents that specifically target Mycobacterium tuberculosis, the bacteria responsible for tuberculosis, which can survive and replicate inside human cells. The researchers are using advanced screening techniques to identify compounds that can effectively kill these intracellular bacteria, which are often resistant to standard treatments. By evaluating promising chemical compounds, the goal is to shorten the duration of tuberculosis therapy and improve patient outcomes. This approach aims to address the challenges posed by antibiotic tolerance and the unique environment in which these bacteria thrive.
Why it matters
Potential benefit: If successful, this research could lead to more effective and shorter treatments for tuberculosis, potentially saving lives and reducing the burden of this disease.
How similar studies have gone: Other research has shown promise in developing targeted therapies for intracellular bacteria, indicating that this approach may lead to significant advancements in tuberculosis treatment.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Parish, Tanya — Seattle Children's Hospital
- Study coordinator: Parish, Tanya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.